UnitedHealth Group, the parent company of OptumRx, has been implicated in significant overcharging practices for essential medications. A recent report by the Federal Trade Commission (FTC) revealed that between 2017 and 2022, the three largest pharmacy benefit managers (PBMs) in the U.S.—OptumRx (a subsidiary of UnitedHealth), Express Scripts, and CVS Caremark—collectively generated approximately $7.3 billion in revenue through substantial price markups on critical drugs, including those for cancer treatment. Some of these medications were marked up by over 1,000% above their acquisition costs.
This revelation comes in the wake of the tragic death of Brian Thompson, the CEO of UnitedHealthcare, who was fatally shot in New York City on December 4, 2024. Thompson had been receiving threats related to medical coverage prior to his death. The suspect, Luigi Mangione, has been arrested and is facing charges for the murder. His attorney has stated that Mangione intends to plead not guilty.
In the aftermath of these events, UnitedHealth Group reported mixed financial results for the fourth quarter. The company's revenue fell short of Wall Street forecasts, partly due to underperformance in its insurance sector. Additionally, an increase in the medical care ratio raised concerns among investors, leading to a decline in UnitedHealth's share value.
These developments have intensified scrutiny of the U.S. healthcare industry, particularly regarding the practices of PBMs and the broader implications for drug pricing and patient care.
https://www.reuters.com/busine....ss/healthcare-pharma
